Business · National
Biocon gets European Commission nod for breast cancer biosimilar
First under new tailored clinical pathway; company’s fifth oncology biosimilar approved in Europe and the US
Verified Timeline
No verified timeline updates.
What is your view on “Biocon gets European Commission nod for breast cancer biosimilar”?
This is self-selected reader participation, not representative scientific polling.

